{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:44:48Z","timestamp":1772631888818,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970140"],"award-info":[{"award-number":["81970140"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370161"],"award-info":[{"award-number":["82370161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clml.2024.12.008","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T04:23:37Z","timestamp":1735014217000},"page":"e243-e252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tyrosine Kinase Inhibitor Treatment Patterns in Patients With Chronic-Phase Chronic Myeloid Leukemia: A Single Center Data From China"],"prefix":"10.1016","volume":"25","author":[{"given":"Meng-yao","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-shuai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clml.2024.12.008_bib0001","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of Imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"10314","key":"10.1016\/j.clml.2024.12.008_bib0002","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","article-title":"Chronic myeloid leukaemia","volume":"398","author":"Cortes","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clml.2024.12.008_bib0003","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/ejh.13524","article-title":"Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data","volume":"106","author":"Gambacorti-Passerini","year":"2021","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2024.12.008_bib0004","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s11096-017-0484-9","article-title":"Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia","volume":"39","author":"Machado-Alba","year":"2017","journal-title":"Int J Clin Pharm"},{"issue":"13","key":"10.1016\/j.clml.2024.12.008_bib0005","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.3390\/jcm11133597","article-title":"Real-world analysis of the therapeutic management and disease burden in chronic myeloid leukemia patients with later lines in Italy","volume":"11","author":"Breccia","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.clml.2024.12.008_bib0006","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/01.HS9.0000843528.26169.66","article-title":"S159: Qu\u00e9bec Cml Research Group analysis of treatment patterns in chronic myelogenous leukemia: Switching is driven by intolerance and similar across tyrosine kinase inhibitors and lines of treatment","volume":"6","author":"Busque","year":"2022","journal-title":"HemaSphere"},{"issue":"5","key":"10.1016\/j.clml.2024.12.008_bib0007","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3390\/jcm9051542","article-title":"Outcomes of chronic phase chronic myeloid leukemia after treatment with multiple tyrosine kinase inhibitors","volume":"9","author":"Kong","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.clml.2024.12.008_bib0008","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.16733","article-title":"Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study","volume":"192","author":"Milojkovic","year":"2021","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.clml.2024.12.008_bib0009","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.6004\/jnccn.2019.7303","article-title":"Long-term patterns of oral anticancer agent adoption, duration, and switching in patients with CML","volume":"17","author":"Banegas","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.clml.2024.12.008_bib0010","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1186\/s12885-022-10241-y","article-title":"A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia","volume":"22","author":"Cantoni","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clml.2024.12.008_bib0011","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/10428194.2019.1644332","article-title":"Treatment patterns and deep molecular response in chronic phase \u2013 chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study","volume":"61","author":"Cortes","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2024.12.008_bib0012","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clinthera.2014.10.019","article-title":"Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States","volume":"37","author":"Henk","year":"2015","journal-title":"Clin Ther"},{"issue":"16","key":"10.1016\/j.clml.2024.12.008_bib0013","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.3390\/cancers15164161","article-title":"A multicenter retrospective chart review study of treatment and disease patterns and clinical outcomes of patients with chronic-phase chronic myeloid leukemia in third-line treatment or with T315I mutation","volume":"15","author":"Nicolini","year":"2023","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.clml.2024.12.008_bib0014","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1185\/03007995.2012.741577","article-title":"Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis","volume":"28","author":"Chen","year":"2012","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"10.1016\/j.clml.2024.12.008_bib0015","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson Comorbidity Index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clinical Epidemiol"},{"issue":"1","key":"10.1016\/j.clml.2024.12.008_bib0016","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson Comorbidity index: a critical review of clinimetric properties","volume":"91","author":"Charlson","year":"2022","journal-title":"Psychother Psychosom"},{"issue":"35","key":"10.1016\/j.clml.2024.12.008_bib0017","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.12.008_bib0018","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.12.008_bib0019","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.12.008_bib0020","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2024.12.008_bib0021","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.leukres.2013.06.003","article-title":"Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABLIS or log reduction from the baseline level?","volume":"37","author":"Qin","year":"2013","journal-title":"Leuk Res"},{"issue":"25","key":"10.1016\/j.clml.2024.12.008_bib0022","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1182\/blood-2011-10-383711","article-title":"Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet","volume":"119","author":"Guilhot","year":"2012","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.12.008_bib0023","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1182\/blood.V130.Suppl_1.897.897","article-title":"Final evaluation of randomized CML-Study IV: 10-year survival and evolution of terminal phase","volume":"130","author":"Hehlmann","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.12.008_bib0024","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/jcpt.12273","article-title":"A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years","volume":"40","author":"Lang","year":"2015","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"10.1016\/j.clml.2024.12.008_bib0025","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/phar.1893","article-title":"Evaluation of long-term chronic myeloid leukemia treatment practices with tyrosine kinase inhibitors in a national cohort of veterans","volume":"37","author":"Kreys","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.clml.2024.12.008_bib0026","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1377\/hlthaff.2017.1684","article-title":"Generic price competition for specialty drugs: too little, too late?","volume":"37","author":"Cole","year":"2018","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"10.1016\/j.clml.2024.12.008_bib0027","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1078155217697484","article-title":"Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system","volume":"24","author":"Rashid","year":"2018","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.clml.2024.12.008_bib0028","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clinthera.2014.10.019","article-title":"Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States","volume":"37","author":"Henk","year":"2015","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.clml.2024.12.008_bib0029","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clml.2024.12.008_bib0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/978-1-4614-6176-0_8","article-title":"Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms","volume":"779","author":"Bisen","year":"2013","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"10.1016\/j.clml.2024.12.008_bib0031","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.12.008_bib0032","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/jcpt.12273","article-title":"A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years","volume":"40","author":"Lang","year":"2015","journal-title":"J Clin Pharm Ther"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:39:40Z","timestamp":1772606380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024024455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2152265024024455"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.12.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tyrosine Kinase Inhibitor Treatment Patterns in Patients With Chronic-Phase Chronic Myeloid Leukemia: A Single Center Data From China","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}